[go: up one dir, main page]

DK3445773T3 - Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf - Google Patents

Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK3445773T3
DK3445773T3 DK17797002.7T DK17797002T DK3445773T3 DK 3445773 T3 DK3445773 T3 DK 3445773T3 DK 17797002 T DK17797002 T DK 17797002T DK 3445773 T3 DK3445773 T3 DK 3445773T3
Authority
DK
Denmark
Prior art keywords
adeno
methods
same
associated virus
virus variant
Prior art date
Application number
DK17797002.7T
Other languages
English (en)
Other versions
DK3445773T5 (da
Inventor
David H Kirn
Melissa Kotterman
David Schaffer
Original Assignee
4D Molecular Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4D Molecular Therapeutics Inc filed Critical 4D Molecular Therapeutics Inc
Publication of DK3445773T3 publication Critical patent/DK3445773T3/da
Application granted granted Critical
Publication of DK3445773T5 publication Critical patent/DK3445773T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
DK17797002.7T 2016-05-13 2017-05-12 Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf DK3445773T5 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662336441P 2016-05-13 2016-05-13
US201662378106P 2016-08-22 2016-08-22
US201662384590P 2016-09-07 2016-09-07
US201762454612P 2017-02-03 2017-02-03
PCT/US2017/032542 WO2017197355A2 (en) 2016-05-13 2017-05-12 Adeno-associated virus variant capsids and methods of use thereof

Publications (2)

Publication Number Publication Date
DK3445773T3 true DK3445773T3 (da) 2023-03-20
DK3445773T5 DK3445773T5 (da) 2024-09-09

Family

ID=60267403

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17797002.7T DK3445773T5 (da) 2016-05-13 2017-05-12 Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf
DK22208172.1T DK4206216T3 (da) 2016-05-13 2017-05-12 Adeno-associerede virusvarianter og fremgangsmåder til brug deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK22208172.1T DK4206216T3 (da) 2016-05-13 2017-05-12 Adeno-associerede virusvarianter og fremgangsmåder til brug deraf

Country Status (27)

Country Link
US (8) US11364308B2 (da)
EP (3) EP4209501A1 (da)
JP (1) JP6592208B2 (da)
KR (1) KR102234930B1 (da)
CN (3) CN109476707B (da)
AU (1) AU2017261812B2 (da)
BR (1) BR112018072849B1 (da)
CA (1) CA3023592C (da)
CL (1) CL2018003196A1 (da)
CO (1) CO2018013255A2 (da)
CR (1) CR20180589A (da)
DK (2) DK3445773T5 (da)
ES (1) ES2941502T3 (da)
FI (2) FI3445773T3 (da)
IL (1) IL262922B (da)
MA (1) MA44740A (da)
MX (2) MX2018013463A (da)
NZ (1) NZ748395A (da)
PE (1) PE20190129A1 (da)
PH (1) PH12018502387A1 (da)
PT (2) PT4206216T (da)
RU (1) RU2725286C2 (da)
SA (1) SA518400418B1 (da)
SG (1) SG11201809684YA (da)
UA (1) UA124343C2 (da)
WO (1) WO2017197355A2 (da)
ZA (2) ZA201807625B (da)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
EP2699270B1 (en) 2011-04-22 2017-06-21 The Regents of The University of California Adeno-associated virus virions with variant capsid and methods of use thereof
CN105247044B (zh) 2013-05-31 2021-05-07 加利福尼亚大学董事会 腺相关病毒变体及其使用方法
KR102537394B1 (ko) 2014-03-17 2023-05-30 애드베룸 바이오테크놀로지스, 인코포레이티드 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
MY187898A (en) 2015-03-02 2021-10-27 Adverum Biotechnologies Inc Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
CN107532177A (zh) 2015-03-24 2018-01-02 加利福尼亚大学董事会 腺相关病毒变体及其使用方法
IL292830B2 (en) 2015-09-28 2023-06-01 Univ Florida Methods and compositions for stealth virus antibody vectors
AU2017261812B2 (en) * 2016-05-13 2019-04-18 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and methods of use thereof
MA44546B1 (fr) * 2016-06-15 2021-03-31 Univ California Virus adéno-associés variants et procédés d'utilisation
CA3029833A1 (en) 2016-07-29 2018-02-01 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
US11192925B2 (en) 2016-10-19 2021-12-07 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
BR112019019015A2 (pt) 2017-06-30 2020-04-14 Univ California vírions de vírus adeno-associado com capsídeos variantes e seus métodos de uso
CN120989074A (zh) 2017-07-31 2025-11-21 映像生物有限公司 眼部疾病的细胞模型及用于眼部疾病的疗法
EP3655041A4 (en) * 2017-08-25 2021-04-21 Ovid Therapeutics Inc RECOMBINANT ADENO-ASSOCIATED VECTORS
BR112020003571A2 (pt) 2017-08-28 2020-08-25 The Regents Of The University Of California variantes capsidiais de vírus adenoassociado e métodos de uso das mesmas
KR20250011726A (ko) * 2017-09-20 2025-01-21 4디 몰레큘러 테라퓨틱스 아이엔씨. 아데노-관련 바이러스 변이체 캡시드 및 그 용도
EP3697448A1 (en) * 2017-10-20 2020-08-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising the subretinal delivery of a therapeutically effective amount of a recombinant aav9-derived vector
KR20250052478A (ko) * 2017-11-27 2025-04-18 4디 몰레큘러 테라퓨틱스 아이엔씨. 아데노-관련 바이러스 변이체 캡시드 및 혈관 신생을 억제하기 위한 용도
EP3758725A4 (en) 2018-02-28 2021-05-19 University of Pittsburgh - of the Commonwealth System of Higher Education MODULAR SYSTEM FOR GENE AND PROTEIN ADMINISTRATION BASED ON AAV
BR112020018354A2 (pt) 2018-03-16 2020-12-29 Research Institute At Nationwide Children's Hospital Aumento de fornecimento gênico específico a tecido através de modificação de capsídeo
AU2019247748A1 (en) 2018-04-03 2020-10-08 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
AU2019247746B2 (en) 2018-04-03 2024-08-15 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
KR20210006358A (ko) 2018-04-03 2021-01-18 스트라이드바이오 인코포레이티드 안 조직을 표적으로 하기 위한 바이러스 벡터
JP2021523702A (ja) * 2018-05-04 2021-09-09 オレゴン ヘルス アンド サイエンス ユニバーシティ ヒト抗ａａｖ２カプシドポリクローナル抗体エピトープ
KR20240033089A (ko) * 2018-06-06 2024-03-12 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 신경 줄기 세포 조성물 및 신경변성 장애를 치료하는 방법
GB201809588D0 (en) * 2018-06-12 2018-07-25 Univ Bristol Materials and methods for modulating intraocular and intracranial pressure
EP3829652A4 (en) * 2018-08-01 2022-05-11 University of Maryland, Baltimore MODULATION OF MTORC1 ACTIVITY AND AUTOPHAGY BY CIB2-RHEB INTERACTION
JP7451497B2 (ja) * 2018-08-21 2024-03-18 マサチューセッツ アイ アンド イヤー インファーマリー アデノ随伴ウイルスの形質導入効率を調節するための組成物および方法
CA3114199A1 (en) 2018-09-26 2020-04-02 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
EP3864160A4 (en) * 2018-10-10 2022-10-26 Wisconsin Alumni Research Foundation KIR 7.1 GENE THERAPY VECTORS AND METHODS OF USING THE SAME
US20220073905A1 (en) * 2018-12-28 2022-03-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for single cell transcriptome-based development of aav vectors and promoters
KR20210130158A (ko) 2019-01-31 2021-10-29 오레곤 헬스 앤드 사이언스 유니버시티 Aav 캡시드의 전사 의존적 유도 진화를 사용하는 방법
JP2022520647A (ja) * 2019-02-15 2022-03-31 サンガモ セラピューティクス， インコーポレイテッド 組み換えａａｖ生産のための組成物および方法
MX2021011468A (es) 2019-03-21 2021-12-15 Vectores de virus adenoasociados recombinantes.
AU2020253435A1 (en) * 2019-04-01 2021-11-18 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
KR20210148333A (ko) * 2019-04-08 2021-12-07 더 칠드런스 호스피탈 오브 필라델피아 Tpp1을 발현하는 aav의 투여를 통한 눈의 리소좀 축적 질환 치료
JP2022530126A (ja) * 2019-04-23 2022-06-27 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 新規アデノ随伴ウイルス（ａａｖ）バリアント及び遺伝子治療のためのその使用
EP3960755A4 (en) * 2019-04-24 2023-11-22 Takara Bio Inc. VAA MUTANT WITH BRAIN-TARGETING PROPERTY
TW202532428A (zh) 2019-04-26 2025-08-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
EP3736330A1 (en) * 2019-05-08 2020-11-11 European Molecular Biology Laboratory Modified adeno-associated virus (aav) particles for gene therapy
US20220265853A1 (en) * 2019-07-12 2022-08-25 Gene Therapy Research Institution Co., Ltd. Adeno-associated virus virion for gene transfer to human liver
DK3999119T3 (da) * 2019-07-15 2024-10-28 Univ Of Heidelberg Modificerede AVV-capsidproteiner til behandling af slidgigtsygdom
JP2022547570A (ja) * 2019-09-12 2022-11-14 ザ・ブロード・インスティテュート・インコーポレイテッド 操作済みのアデノ随伴ウイルスキャプシド
JP2022551986A (ja) 2019-10-16 2022-12-14 ザ・ブロード・インスティテュート・インコーポレイテッド 修飾筋肉標的化組成物
WO2021076925A1 (en) 2019-10-17 2021-04-22 Stridebio, Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
WO2021080991A1 (en) * 2019-10-21 2021-04-29 The Trustees Of The University Of Pennsylvania Aav3b variants with improved production yield and liver tropism
CN110724673B (zh) * 2019-10-31 2021-08-06 上海爱尔眼科医院有限公司 嗜外层视网膜的腺相关病毒病毒体及其应用
WO2021084133A1 (en) * 2019-10-31 2021-05-06 Universität Bern Aav vector variants for ocular gene delivery
GB202005641D0 (en) * 2020-04-17 2020-06-03 Ucl Business Plc Gene therapy for bardet-biedl syndrome
AU2021226603A1 (en) * 2020-02-28 2022-10-27 The Trustees Of The University Of Pennsylvania Treating autosomal recessive bestrophinopathies and methods for evaluating same
US20230108025A1 (en) * 2020-03-13 2023-04-06 Wisconsin Alumni Research Foundation Kir 7.1 gene therapy vectors and methods of using the same
EP4121443A4 (en) * 2020-03-20 2024-05-15 Dignity Health METHOD FOR THE PRODUCTION AND ISOLATION OF ADENO-ASSOCIATED VIRUS
CN115515613A (zh) 2020-04-27 2022-12-23 4D分子治疗有限公司 密码子优化的gla基因及其用途
CA3179597A1 (en) * 2020-05-29 2021-12-02 John G. Flannery Adeno-associated virus virions with variant capsids and methods of use thereof
EP4179098A4 (en) * 2020-07-08 2024-10-23 Baylor College Of Medicine GENE THERAPY FOR STXBP1 ENCEPHALOPATHY
CN111849998A (zh) * 2020-07-29 2020-10-30 武汉纽福斯生物科技有限公司 编码人卵黄状黄斑病蛋白1的核酸分子及其应用
CN111733174B (zh) * 2020-08-07 2021-02-09 北京大学第三医院（北京大学第三临床医学院） 一种分离的核酸分子及其用途
IL300717A (en) 2020-08-19 2023-04-01 Sarepta Therapeutics Inc ADENO-related virus vectors for the treatment of RETT syndrome
AU2021337530B2 (en) * 2020-09-02 2023-08-24 4D Molecular Therapeutics Inc. Codon Optimized RPGRorf 15 Genes And Uses Thereof
WO2022087104A1 (en) * 2020-10-21 2022-04-28 Chan Zuckerberg Biohub, Inc. Adeno-associated virus virions and methods of use thereof
EP4244209A1 (en) 2020-11-11 2023-09-20 European Molecular Biology Laboratory Modified viral particles for gene therapy
CN115044614B (zh) * 2021-03-09 2023-10-20 上海目镜生物医药科技有限公司 一种用于基因靶向与表达的aav-8型血清型的改造型载体及其构建方法及应用
US12385064B2 (en) 2021-03-26 2025-08-12 Adverum Biotechnologies, Inc. Intravitreal dosing for delivery of polynucleotides to retinal cones
WO2022232178A1 (en) 2021-04-27 2022-11-03 4D Molecular Therapeutics Inc. Compositions and methods for treatment of ocular disease associated with angiogenesis
MX2023014041A (es) * 2021-05-28 2023-12-15 Shanghai Regenelead Therapies Co Ltd Virus adenoasociado recombinante que tiene una capsida variante y su aplicacion.
WO2023283962A1 (en) * 2021-07-16 2023-01-19 Huigene Therapeutics Co., Ltd. Modified aav capsid for gene therapy and methods thereof
CN118076744A (zh) * 2021-07-23 2024-05-24 杜克大学 腺相关病毒组合物及其使用方法
WO2023044306A1 (en) * 2021-09-14 2023-03-23 California Institute Of Technology Aav capsid variants
IL311871A (en) 2021-10-08 2024-06-01 Dyno Therapeutics Inc Capsid variants and methods of using them
CN114057840B (zh) * 2021-10-14 2022-09-20 和元生物技术（上海）股份有限公司 包含变异的aav9衣壳蛋白的重组腺相关病毒颗粒
EP4446418A4 (en) * 2021-12-06 2025-11-19 Juntendo Educational Found MODIFIED ADENO-ASSOCIATED VIRUS VECTOR
US20250297279A1 (en) * 2021-12-15 2025-09-25 Genans Biotechnology Co., Ltd Recombinant aav vectors and use thereof
CN116925192B (zh) * 2022-04-12 2025-04-29 合肥星眸生物科技有限公司 一种融合型腺相关病毒及其应用
CN119630688A (zh) * 2022-04-15 2025-03-14 迪诺治疗股份有限公司 衣壳变体及其使用方法
EP4514984A1 (en) * 2022-04-25 2025-03-05 Beijing Hanmoluojie Technology Co., Ltd. Aav capsid 3d molecular surface feature mapping
US20260000786A1 (en) * 2022-07-14 2026-01-01 Fondation Asile Des Aveugles Gene therapy for fam161a-associated retinopathies and other ciliopathies
CN119894920A (zh) * 2022-07-22 2025-04-25 上海天泽云泰生物医药有限公司 用于靶向神经系统的新型aav衣壳及其用途
CN115968834A (zh) * 2023-01-20 2023-04-18 北京因诺惟康医药科技有限公司 一种rs1点突变小鼠模型的制备方法及其用途
CN118420721A (zh) * 2023-01-31 2024-08-02 上海朗昇生物科技有限公司 一种组织嗜性的腺相关病毒衣壳及其用途
TW202502803A (zh) 2023-03-10 2025-01-16 美商戴諾治療公司 衣殼多肽及其使用方法
EP4689140A2 (en) * 2023-04-07 2026-02-11 4D Molecular Therapeutics Inc. Aav variants for treatment of complement disorders
WO2024220966A1 (en) * 2023-04-21 2024-10-24 The Regents Of The University Of California Novel glycan compounds for age-related macular degeneration
AU2024276934A1 (en) * 2023-05-23 2025-12-18 Innovec Biotherapeutics Adeno-associated virus capsid protein, adeno-associated virus containing same, vector and use thereof
WO2025049993A1 (en) 2023-08-31 2025-03-06 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
CN120230798A (zh) * 2023-12-29 2025-07-01 上海朗昇生物科技有限公司 用于视网膜基因递送的重组腺相关病毒载体及其应用
CN118440161B (zh) * 2024-01-16 2025-02-25 沈阳兴齐眼药股份有限公司 提高aav病毒视网膜穿透能力的衣壳蛋白突变体及其应用
WO2025171227A1 (en) 2024-02-08 2025-08-14 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
WO2025214359A1 (en) * 2024-04-09 2025-10-16 Hangzhou Jiayin Biotech Ltd. A novel aav variant
CN118222631B (zh) * 2024-05-24 2024-10-15 广州湾区生物基因科技有限公司 用于靶向治疗遗传性视网膜变性的病毒载体组合
CN119751597B (zh) * 2024-07-16 2025-08-01 广州派真生物技术有限公司 腺相关病毒突变体及其应用
WO2026024048A1 (ko) * 2024-07-22 2026-01-29 한국생명공학연구원 변이체 캡시드를 포함하는 아데노-연관 바이러스 및 이의 용도
CN118667036B (zh) * 2024-08-20 2025-01-10 上海玮美基因科技有限责任公司 一种融合型腺相关病毒衣壳蛋白、腺相关病毒及其应用

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215422A1 (en) 1996-09-11 2003-11-20 John A. Chiorini Aav4 vector and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US7323179B2 (en) 1997-12-19 2008-01-29 Naomi Balaban Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6984517B1 (en) 1998-05-28 2006-01-10 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector and uses thereof
CA2329060C (en) 1998-05-28 2011-09-13 John A. Chiorini Aav5 vector and uses thereof
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
PT1127150E (pt) 1998-11-05 2007-08-22 Univ Pennsylvania ''sequências de ácido nucleico do vírus adeno associado do serotipo 1, vectores e células hospedeiras que as contêm''
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6498244B1 (en) * 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
EP1309726B2 (en) 2000-03-30 2018-10-03 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
AU2001264862B2 (en) 2000-05-23 2006-03-30 University Of Rochester Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
US20100305186A1 (en) 2000-05-30 2010-12-02 Johnson & Johnson Research Pty Limited Methods for mediating gene suppression
CN1311081C (zh) 2000-08-19 2007-04-18 爱克斯澳迪亚有限公司 干细胞分化
IL154987A0 (en) * 2000-09-22 2003-10-31 Virxsys Conditionally replicating viral vectors and their use
WO2002029858A2 (en) 2000-09-29 2002-04-11 Infineon Technologies North America Corp. Deep trench etching method to reduce/eliminate formation of black silicon
US7749492B2 (en) 2001-01-05 2010-07-06 Nationwide Children's Hospital, Inc. AAV vectors and methods
WO2002053703A2 (en) 2001-01-05 2002-07-11 Children's Hospital, Inc. Aav2 vectors and methods
CA2467959C (en) 2001-11-09 2009-03-10 Robert M. Kotin Production of adeno-associated virus in insect cells
SG10201506627PA (en) 2001-11-13 2015-10-29 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
ES2975413T3 (es) 2001-12-17 2024-07-05 Univ Pennsylvania Secuencias de serotipo 8 de virus adenoasociado (AAV), vectores que las contienen y usos de las mismas
ES2526341T3 (es) 2001-12-17 2015-01-09 The Trustees Of The University Of Pennsylvania Secuencias de serotipo 9 de virus adeno-asociado (AAV), vectores que las contienen, y usos de las mismas
CA2468882C (en) 2001-12-21 2015-09-29 Medigene Ag A library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism
US20040002159A1 (en) 2002-04-05 2004-01-01 Weidong Xiao Methods for the production of chimeric adeno-associated virus (AAV) vectors, compositions of chimeric AAV vectors, and methods of use thereof
WO2003089612A2 (en) 2002-04-17 2003-10-30 University Of Florida Research Foundation, Inc. IMPROVED rAAV VECTORS
AU2003295312B2 (en) 2002-05-01 2008-08-14 University Of Florida Research Foundation, Inc. Improved rAAV expression systems for genetic modification of specific capsid proteins
WO2003093479A1 (en) * 2002-05-01 2003-11-13 University Of Florida Research Foundation, Inc. Improved raav expression systems and methods for enhancing transduction of mammalian neural cells
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
AU2003265855A1 (en) 2002-08-28 2004-03-19 University Of Florida Modified aav
US7186522B2 (en) 2003-03-31 2007-03-06 Cytyc Corporation Papanicolau staining process
US20060286545A1 (en) 2003-05-23 2006-12-21 Mount Sinai School Of Medicine Of New York University Viral vectors with improved properties
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
US8071028B2 (en) 2003-06-12 2011-12-06 Abbott Diabetes Care Inc. Method and apparatus for providing power management in data communication systems
PT2657248T (pt) 2003-06-19 2017-06-26 Genzyme Corp Viriões aav com imunorreatividade diminuída e seus usos
US9233131B2 (en) * 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
CN102212558B (zh) 2003-09-30 2016-08-03 宾夕法尼亚大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
ES2556710T3 (es) 2004-09-24 2016-01-19 Novartis Ag Proteínas capsidiales VP1 modificadas del parvovirus B19
NZ555830A (en) 2004-12-15 2009-01-31 Univ North Carolina Chimeric vectors
CN101203613B (zh) 2005-04-07 2012-12-12 宾夕法尼亚大学托管会 增强腺相关病毒载体功能的方法
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
SI1945779T1 (sl) 2005-10-20 2013-07-31 Uniqure Ip B.V. Izboljĺ ani aav vektorji proizvedeni v celicah insekta
WO2007089632A2 (en) 2006-01-27 2007-08-09 The University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
US20090317417A1 (en) 2006-04-28 2009-12-24 The Trustees Of The University Of Pennsylvania Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof
PL2191001T4 (pl) 2007-04-09 2017-01-31 University Of Florida Research Foundation, Inc. Kompozycje wektora RAAV mające białka kapsydu zmodyfikowane tyrozyną i sposoby ich zastosowania
WO2008124015A1 (en) 2007-04-09 2008-10-16 The Regents Of The University Of California Methods for purifying adeno-associated virus virions
US20100203083A1 (en) 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
EP2012122A1 (en) 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
EP3121190A1 (en) * 2007-07-14 2017-01-25 University of Iowa Research Foundation Methods and compositions for treating brain diseases
US20090215879A1 (en) 2008-02-26 2009-08-27 University Of North Carolina At Chapel Hill Methods and compositions for adeno-associated virus (aav) with hi loop mutations
US8632764B2 (en) 2008-04-30 2014-01-21 University Of North Carolina At Chapel Hill Directed evolution and in vivo panning of virus vectors
EP2297185A1 (en) 2008-06-17 2011-03-23 Amsterdam Molecular Therapeutics (AMT) B.V. Parvoviral capsid with incorporated gly-ala repeat region
JP2010002479A (ja) 2008-06-18 2010-01-07 Crossfor:Kk メガネレンズ用装飾体およびメガネ用装飾体装着具
US20110275529A1 (en) 2008-09-19 2011-11-10 Charite Universitatsmedizin Berlin Identification and characterisation of recombinant viral gene therapy vectors
WO2010093784A2 (en) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
WO2010141706A1 (en) 2009-06-03 2010-12-09 Cedars-Sinai Medical Center Effective vector platform for gene transfer and gene therapy
WO2011038187A1 (en) 2009-09-25 2011-03-31 The Trustees Of The University Of Pennsylvania Controlled adeno-associated virus (aav) diversification and libraries prepared therefrom
US8299295B2 (en) 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8263396B2 (en) 2010-04-01 2012-09-11 Weidong Xiao Methods and compositions for the production of recombinant virus vectors
ES2698203T3 (es) 2010-04-23 2019-02-01 Univ Massachusetts Vectores de AAV que se dirigen al SNC y métodos de uso de los mismos
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
EP3156062A1 (en) 2010-05-17 2017-04-19 Sangamo BioSciences, Inc. Novel dna-binding proteins and uses thereof
US8663624B2 (en) * 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
US10415056B2 (en) 2010-11-10 2019-09-17 Fred Hutchinson Cancer Research Center Compositions and methods for generating adeno-associated viral vectors with undetectable capsid gene contamination
DK2673289T3 (da) 2011-02-10 2023-07-24 Univ North Carolina Chapel Hill Virusvektorer med modificerede transduktionsprofiler og fremgangsmåder til fremstilling og anvendelse deraf
US10392632B2 (en) 2011-02-14 2019-08-27 The Children's Hospital Of Philadelphia AAV8 vector with enhanced functional activity and methods of use thereof
WO2012112832A1 (en) 2011-02-17 2012-08-23 The Trustees Of The University Of Pennsylvania Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
EP2699270B1 (en) 2011-04-22 2017-06-21 The Regents of The University of California Adeno-associated virus virions with variant capsid and methods of use thereof
ES2857773T5 (es) 2011-08-24 2024-06-04 Univ Leland Stanford Junior Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
WO2013096955A1 (en) 2011-12-23 2013-06-27 Case Western Reserve University Targeted gene modification using hybrid recombinant adeno-associated virus
SG11201404956PA (en) 2012-02-17 2014-09-26 Philadelphia Children Hospital Aav vector compositions and methods for gene transfer to cells, organs and tissues
PE20150163A1 (es) 2012-04-18 2015-02-23 Philadelphia Children Hospital Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav
EP2660325A3 (en) 2012-05-02 2014-02-12 Christian Medical College AAV vectors and corresponding nucleotide sequences and methods
US9677088B2 (en) 2012-05-09 2017-06-13 Oregon Health & Science University Adeno associated virus plasmids and vectors
WO2013174760A1 (en) 2012-05-25 2013-11-28 Deutsches Krebsforschungszentrum Optimized aav-vectors for high transduction rates in dendritic cells
EP2692731A1 (en) 2012-07-31 2014-02-05 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Recombinant Adeno-Associated virus (AAV) vector particles displaying high-affinity ligands for cell-type specific gene delivery
WO2014052789A1 (en) 2012-09-28 2014-04-03 The University Of North Carolina At Chapel Hill Aav vectors targeted to oligodendrocytes
EP2940131B1 (en) 2012-12-25 2019-02-20 Takara Bio Inc. Aav variant
WO2014124282A1 (en) 2013-02-08 2014-08-14 The Trustees Of The University Of Pennsylvania Enhanced aav-mediated gene transfer for retinal therapies
EP2970946A4 (en) 2013-03-13 2016-09-07 Philadelphia Children Hospital ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF
CN105247044B (zh) 2013-05-31 2021-05-07 加利福尼亚大学董事会 腺相关病毒变体及其使用方法
ES2768763T3 (es) 2014-03-04 2020-06-23 Univ Florida Vectores rAAV mejorados y métodos para la transducción de fotorreceptores y células EPR
WO2015164757A1 (en) * 2014-04-25 2015-10-29 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
AU2017261812B2 (en) * 2016-05-13 2019-04-18 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and methods of use thereof
MA44546B1 (fr) 2016-06-15 2021-03-31 Univ California Virus adéno-associés variants et procédés d'utilisation
CA3029833A1 (en) 2016-07-29 2018-02-01 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof

Also Published As

Publication number Publication date
US11364308B2 (en) 2022-06-21
US20240066145A1 (en) 2024-02-29
CL2018003196A1 (es) 2019-02-15
PE20190129A1 (es) 2019-01-17
DK4206216T3 (da) 2025-12-01
WO2017197355A2 (en) 2017-11-16
MX2023009627A (es) 2023-08-28
US20190255192A1 (en) 2019-08-22
WO2017197355A3 (en) 2017-12-28
IL262922B (en) 2019-09-26
US11179477B2 (en) 2021-11-23
US20230211013A1 (en) 2023-07-06
UA124343C2 (uk) 2021-09-01
EP4209501A1 (en) 2023-07-12
CN109476707A (zh) 2019-03-15
US20210177990A1 (en) 2021-06-17
MX2018013463A (es) 2019-07-04
ZA201905485B (en) 2021-03-31
FI3445773T3 (fi) 2023-03-30
KR102234930B1 (ko) 2021-04-02
US20210162071A1 (en) 2021-06-03
BR112018072849A2 (pt) 2019-03-06
US20210069349A1 (en) 2021-03-11
AU2017261812B2 (en) 2019-04-18
MA44740A (fr) 2019-02-27
CA3023592C (en) 2020-12-08
FI4206216T3 (fi) 2025-12-17
SA518400418B1 (ar) 2022-12-20
EP3445773A4 (en) 2019-10-02
EP4206216B1 (en) 2025-10-08
RU2018142768A3 (da) 2020-06-16
PT4206216T (pt) 2025-12-03
RU2018142768A (ru) 2020-06-16
US20230001018A1 (en) 2023-01-05
EP3445773A2 (en) 2019-02-27
US11576983B2 (en) 2023-02-14
JP2019518458A (ja) 2019-07-04
KR20190005223A (ko) 2019-01-15
US11419949B2 (en) 2022-08-23
CN109476707B (zh) 2022-12-02
BR112018072849B1 (pt) 2020-12-22
CO2018013255A2 (es) 2018-12-14
CA3023592A1 (en) 2017-11-16
IL262922A (en) 2018-12-31
US11167041B2 (en) 2021-11-09
ZA201807625B (en) 2020-02-26
US20210069348A1 (en) 2021-03-11
US11766487B2 (en) 2023-09-26
CN115925999A (zh) 2023-04-07
CR20180589A (es) 2019-02-27
EP3445773B1 (en) 2022-12-28
AU2017261812A1 (en) 2018-11-15
PH12018502387A1 (en) 2019-03-25
JP6592208B2 (ja) 2019-10-16
EP4206216A1 (en) 2023-07-05
NZ748395A (en) 2019-12-20
ES2941502T3 (es) 2023-05-23
SG11201809684YA (en) 2018-11-29
PT3445773T (pt) 2023-03-13
CN116333057A (zh) 2023-06-27
RU2725286C2 (ru) 2020-06-30
DK3445773T5 (da) 2024-09-09

Similar Documents

Publication Publication Date Title
DK3684423T3 (da) Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf
DK3445773T5 (da) Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf
DK3472183T5 (da) Variant adeno-associerede virus og fremgangsmåder til anvendelse
IL271025A (en) Multibiotic agents and methods of using the same
IL282372A (en) Haploid induction compositions and methods for use therefor
EP3528785A4 (en) MODIFIED AVA CAPSIDES AND THEIR USES
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
EP3589277A4 (en) MODIFIED AVA CAPSIDES AND USE OF THESE LATEST
DK3445388T3 (da) Materialer og fremgangsmåder til behandling af hæmoglobinopatier
PT3259253T (pt) Sulfonilureias e compostos relacionados e uso dos mesmos
DK3805376T3 (da) Modificeret virus
DK3565568T3 (da) Ændret virus
PT3274370T (pt) Anticorpos anti-ceacam6 e utilizações dos mesmos
IL268815A (en) Compositions and methods for tumor transduction
IL258259B (en) Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
IL258956A (en) Compositions and methods for tumor transduction
DK3331879T3 (da) Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
CL2018001139A1 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos.
DK3490988T3 (da) Ny forbindelse og fremgangsmåde
DK3229827T3 (da) Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme
IL246643B (en) Compositions and kits for treating human immunodeficiency virus/accquired immunodeficiency syndrome
DK3371324T3 (da) Virusbiomarkører og anvendelser deraf
EP3614926C0 (en) COLLIMATOR AND RADIOLOGICAL EQUIPMENT
IT201700039351A1 (it) Miscela antimeristematica e antigermogliante